LFG
TRDA icon

Larson Financial Group’s Entrada Therapeutics TRDA Stock Holding History

Larson Financial Group’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-131
Closed -$1.18K – 3496
2025
Q1 		$1.18K Buy
+131
New +$1.63K ﹤0.01% 2338

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

Larson Financial Group's TRDA Position: Q2 2025 in Review

Larson Financial Group sold out of Entrada Therapeutics (TRDA) in Q2 2025, closing a stake of 131 shares — an estimated $1.18K sold.

Larson Financial Group first reported a position in TRDA in Q1 2025 and held it in 1 quarter. The position peaked at $1.18K in Q1 2025. 107 funds tracked by Wall St. Rank hold TRDA as of Q2 2025.

  • Larson Financial Group reported no remaining Entrada Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Larson Financial Group sold 131 Entrada Therapeutics shares in Q2 2025, an estimated $1.18K.
  • Larson Financial Group first reported a position in Entrada Therapeutics in Q1 2025 and held it in 1 quarter.
  • Larson Financial Group's Entrada Therapeutics position peaked at $1.18K in Q1 2025.
  • 107 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2025.

Based on Larson Financial Group's 13F filing for Q2 2025, filed 8 Aug 2025.